Novo Nordisk Shares Face Challenges as Competitor Eli Lilly Enters the $1 Trillion Market Valuation Club

Written by Emily J. Thompson, Senior Investment Analyst

PFE+1.71%

LLY-0.36%

MTSR%

Source: TipRanks

Updated: Nov 21 2025

0mins

Source: TipRanks

Eli Lilly's Market Achievement: Eli Lilly reached a market capitalization of $1 trillion, joining a select group of non-tech companies, while Novo Nordisk's shares have dropped nearly 44% this year, leading to a recalibration of its operations.
Leadership Changes at Novo Nordisk: Lars Rebien Sørensen has been appointed as the new board chair, aiming to support CEO Mike Doustdar's transformation plans after the ousting of the previous leader due to declining shares.
Job Cuts and Market Competition: Novo Nordisk is reducing its workforce in both the U.S. and Denmark as it faces slower sales growth and competition from Eli Lilly's successful weight-loss drug Zepbound.
Analyst Ratings and Future Outlook: Analysts maintain a Moderate Buy consensus on Novo Nordisk, with an average price target suggesting a potential 20% upside, despite recent challenges and a failed acquisition of the startup Metsera.

PFE

$25.58+Infinity%1D

Analyst Views on PFE

Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 29.08 USD with a low forecast of 24.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

15 Analyst Rating

4 Buy

10 Hold

1 Sell

Hold

Current: 25.150

Low

24.00

Averages

29.08

High

34.00

Current: 25.150

Low

24.00

Averages

29.08

High

34.00

UBS

Neutral

initiated

$25

Al Analysis

2026-01-06

Reason

UBS

Price Target

$25

Al Analysis

2026-01-06

initiated

Neutral

Reason

UBS assumed coverage of Pfizer with a Neutral rating and $25 price target. The firm noted a backdrop of continued revenue uncertainty with $15B-$20B in revenues from key drugs losing patient exclusivity over the coming roughly three years. Though the firm is positive on the recent MTSR obesity deal, Pfizer needs to do more to offset 2028 LOE risk, the analyst tells investors in a research note.

BofA

Jason Gerberry

Neutral

downgrade

$28 -> $27

2025-12-16

Reason

BofA

Jason Gerberry

Price Target

$28 -> $27

2025-12-16

downgrade

Neutral

Reason

BofA analyst Jason Gerberry lowered the firm's price target on Pfizer to $27 from $28 and keeps a Neutral rating on the shares after the company "notably called out" faster COVID-19 product erosion relative to prior guidance as part of its 2026 outlook call. The firm, which "modestly" reduced its 2026 Pfizer sales and EPS estimates and its FY27 EPS estimate following the guidance call, looks to planned obesity data updates from the Metsera acquisition to better understand the company's potential obesity differentiation.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PFE

Unlock Now

BofA

Jason Gerberry

Neutral

downgrade

$29 -> $28

2025-12-15

Reason

BofA

Jason Gerberry

Price Target

$29 -> $28

2025-12-15

downgrade

Neutral

Reason

BofA analyst Jason Gerberry lowered the firm's price target on Pfizer to $28 from $29 and keeps a Neutral rating on the shares. The firm, which struggles to see a rerating catalyst as the company works through its multi-year loss of exclusivity period, is shifting its valuation basis to its FY27 EPS estimate.

Morgan Stanley

Equal Weight

downgrade

$32 -> $28

2025-12-12

Reason

Morgan Stanley

Price Target

$32 -> $28

2025-12-12

downgrade

Equal Weight

Reason

Morgan Stanley lowered the firm's price target on Pfizer to $28 from $32 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.

About PFE

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Novo Nordisk Shares Face Challenges as Competitor Eli Lilly Enters the $1 Trillion Market Valuation Club

Analyst Views on PFE

About PFE

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

TSMC Reports 35% YoY Net Income Growth in Q4, Forecasts Nearly 30% Revenue Growth in 2026

Keurig Dr Pepper (KDP) Launches €31.85 Cash Offer for JDE Peet's (JDEPF)

Sigh Up to Get Intellectia Insights

Why did Pfizer withdraw its obesity drug candidate Danuglipron in 2025?

What are the key reasons behind Pfizer's acquisition of Metsera for $10 billion?

How will Pfizer's acquisition of Metsera impact its competitiveness in the obesity market?

What is the likelihood of Pfizer regaining market value after its patent expirations?

What are the financial implications of Pfizer's patent cliff on its 2026 revenue?

People Also Watch